Lilly Builds On Innovent Biologics Bet
This article was originally published in PharmAsia News
Lilly has expanded its cancer drug collaboration with Chinese biotech Innovent Biologics with plans to develop and market up to three anti-PD-1 based bi-specific antibodies over the next decade, both inside China's expanding healthcare market and abroad.
You may also be interested in...
A Phase III clinical trial comparing AbbVie's Skyrizi with Novartis's IL-17 agonist Cosentyx showed the former's superiority in adults with moderate-to-severe plaque psoriasis.
Acasti’s omega-3 candidate drug CaPre missed the primary endpoint in TRILOGY-1 due to an unexplained high placebo effect, as AstraZeneca said its STRENGTH study was unlikely to show a treatment benefit.
MorphoSys has chosen Incyte as its global partner for commercializing and further developing its lead asset, the Fc-engineered antibody tafasitamab that targets CD19.